NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Go back to NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
(NASDAQ: NTHI) Delayed: 5.03 +0.24 (5.01%)
Previous Close $4.79    52 Week High
Open $4.76    52 Week Low
Day High $5.20    P/E N/A 
Day Low $4.74    EPS
Volume 102,431